Blood markers of thinking changes after brain radiotherapy in people with brain tumors
Looks at blood markers and APOE genotype in adults with brain tumors having radiotherapy.
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the site
- Trial code
- Registry title
- Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 2 Nov 2026
- Expected to end
- 31 Aug 2029
- Type of study
- Observational
- Treatments tested
- Blood sample
- Brain magnetic resonance imaging (MRI)
- Brain Health Assessment
- Quality of Life (QoL) Questionnaire
- Record updated
- 16 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a brain tumor that started in the brain, or a cancer that has spread to the brain, who will have standard focused brain radiotherapy. It studies blood markers, the APOE gene and memory and thinking.
- Age
- 18 years and older
- Sex
- All
- Disease stage
- Either a primary brain tumor or a solid cancer that spread to the brain, not both. If the cancer spread to the brain: fewer than 5 spots, none larger than 1 cm (0.4 in). Daily activity level ECOG 0 or 1. Expected to live more than 2 years after treatment.
- Earlier treatment
- No earlier brain radiotherapy, including whole brain radiotherapy. Must be planned for standard focused brain radiotherapy.
Main reasons for not taking part
- Alzheimer's disease, Parkinson's disease or another disease that damages the brain over time
- A memory disorder before treatment
- Cancer in the thin layers covering the brain and spinal cord (leptomeningeal disease)
- Disease in either hippocampus, the brain's memory area
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- >= 18 years old
- Diagnosis of a primary brain tumor OR #3. Not both #2 and #3
- Diagnosis of primary solid tumor and secondary involvement of the brain
- If the patient has brain metastases: fewer than 5 brain metastases (post-operative and definitive allowed), none > 1 cm in max diameter
- Candidate for standard of care / usual care (SOC) focused brain radiotherapy
- No prior brain radiotherapy, including whole brain radiotherapy
- Eastern Cooperative Oncology Group (ECOG) functional score 0 or 1
- Estimated life expectancy post-treatment of > 2 years
Who cannot take part
- Diagnosis of neurodegenerative disease (Alzheimer's disease, Parkinson's disease)
- Diagnosis of memory disorder pre-treatment
- Leptomeningeal disease or disease involving either hippocampus
This trial is currently available in United States.
- University of California San FranciscoSan Francisco, United StatesContact: Jean Nakamura, MDTaking people
About the trial
What the trial wants to find out
This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.
The group in the trial
- Adults with Brain Tumor Receiving Radiotherapy
The study entails longitudinal assessment of plasma biomarkers (Aβ, GFAP, phospho Tau, NfL), determination of APOE genotype, neuropsychiatric testing Brain Health Assessment test (BHA), a clinically validated neurocognitive battery compiling metrics on memory and language), and brain morphometric measurements synchronized with standard of care brain MRIs.
Treatment: Blood sample, Brain magnetic resonance imaging (MRI), Brain Health Assessment, and Quality of Life (QoL) Questionnaire
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer
- Plain-language title
- Blood markers of thinking changes after brain radiotherapy in people with brain tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 17 November 2026.
- Record updated
- 16 November 2026